Progress and novel strategies in vaccine development and treatment of anthrax.
about
Bacillus anthracis edema factor substrate specificity: evidence for new modes of actionNew generation of oral mucosal vaccines targeting dendritic cellsAlternative pre-approved and novel therapies for the treatment of anthraxAntitoxin Treatment of Inhalation Anthrax: A Systematic ReviewIdentification of novel and cross-species seroreactive proteins from Bacillus anthracis using a ligation-independent cloning-based, SOS-inducible expression systemEfficacy of Single and Combined Antibiotic Treatments of Anthrax in RabbitsApproval of Raxibacumab for the Treatment of Inhalation Anthrax Under the US Food and Drug Administration "Animal Rule".New developments in vaccines, inhibitors of anthrax toxins, and antibiotic therapeutics for Bacillus anthracis.Long-range stabilization of anthrax protective antigen upon binding to CMG2.Immunoproteomically identified GBAA_0345, alkyl hydroperoxide reductase subunit C is a potential target for multivalent anthrax vaccine.Designing of interferon-gamma inducing MHC class-II binders.Anthrax and the inflammasomeDifferential contribution of Bacillus anthracis toxins to pathogenicity in two animal modelsNext-Generation Bacillus anthracis Live Attenuated Spore Vaccine Based on the htrA(-) (High Temperature Requirement A) Sterne Strain.MHC class II and non-MHC class II genes differentially influence humoral immunity to Bacillus anthracis lethal factor and protective antigen.Combinations of monoclonal antibodies to anthrax toxin manifest new properties in neutralization assays.Small-molecule inhibitors of lethal factor protease activity protect against anthrax infection.Unique Inflammatory Mediators and Specific IgE Levels Distinguish Local from Systemic Reactions after Anthrax Vaccine Adsorbed VaccinationA Simple Luminescent Adenylate-Cyclase Functional Assay for Evaluation of Bacillus anthracis Edema Factor Activity.DNA vaccines: roles against diseases.Protective-antigen (PA) based anthrax vaccines confer protection against inhalation anthrax by precluding the establishment of a systemic infection.Anthrax toxin protective antigen--insights into molecular switching from prepore to poreAnthrax vaccines: present status and future prospects.Raxibacumab: potential role in the treatment of inhalational anthraxHost immunity to Bacillus anthracis lethal factor and other immunogens: implications for vaccine design.Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated.Whole-Genome Sequencing of the Nonproteolytic Bacillus anthracis V770-NP1-R Strain Reveals Multiple Mutations in Peptidase Loci.De novo asymmetric synthesis of oligo-rhamno di- and tri-saccharides related to the anthrax tetrasaccharideHtrA is a major virulence determinant of Bacillus anthracis.Structure of the Bacillus anthracis dTDP-L-rhamnose-biosynthetic enzyme dTDP-4-dehydrorhamnose 3,5-epimerase (RfbC).Late-Exponential Gene Expression in codY-Deficient Bacillus anthracis in a Host-Like Environment.Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia.
P2860
Q27000357-8A604FAE-C7DF-4F48-BB14-15AAD8FEE361Q27025193-AB39D71F-4EEE-43B6-BCD8-C74B44CE9E24Q28075453-92BCBEEB-FAA2-4265-8C27-FC121B859BD7Q28383765-E9437116-CEDB-477B-8F88-AC4B9B1CC742Q28388913-9B62FF17-3691-4E38-912A-E9E92211792EQ28394063-2BE91F43-3636-4F5D-B08E-487379E557B4Q30201937-4B2D89B1-0E2C-49FE-A56B-BC287AA6B44EQ34066161-15F44509-58AF-40F4-91B8-FBBF61B194D9Q34264855-7C72409F-91B8-4234-8095-7061B856E576Q35052264-0F921470-EBE2-46C3-8FDC-CB86087999CFQ35058917-364E11BD-B82F-4C1B-8CE1-DBE80CDF1E92Q35878129-9232A239-22B5-4FD4-BA19-7254D8B18067Q36211202-A5EF40AD-2AE6-4614-B838-A18D656BB531Q36432828-842E29C4-BECD-4C83-9888-4C09C2150D43Q36482706-651795BE-E7C2-4E35-88F9-AAC0F12A97DDQ36911369-596E240F-A7B8-4632-A81D-F33CA470865FQ37124221-FFE95C41-9BC0-468F-9B7A-5A64673856A4Q37163693-022C3E1C-FD70-423C-A467-B49931C54349Q37209044-1E33392C-1A8F-4007-BAF9-53A614A3C5BBQ37441566-DE067DA1-C991-42C9-B515-8345756596C4Q37530303-20EFE795-512A-4035-93A0-EDC5835C13ECQ37957788-1C368FE8-5692-4010-9A79-DE17F0739D78Q38132268-563F14C7-2936-4B95-BEC5-2D2400E1D196Q38210540-F0A397D8-F7A3-4481-A703-DF4526BDF10BQ38268596-8D26690A-B7D2-45C2-8836-E526A3DB0558Q40213025-DFCFE223-A79B-4732-968F-90B119E8C2EAQ41955033-8EB21B29-D4FA-4124-9CB2-13AC74AE0762Q42074969-B6C628E8-B928-4C1E-BF66-3121C58ACAB7Q46733845-5F8FBE3B-8E41-45EC-AB02-5590C954B096Q47336238-CC5D0A12-6801-48C4-A4AE-8FD5167CCE74Q51576287-8B4C6F7F-8BCA-4682-98AF-A089CE09B0E0Q55361721-FF6D0469-0E1D-4299-8995-B5E187FAC6DE
P2860
Progress and novel strategies in vaccine development and treatment of anthrax.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Progress and novel strategies in vaccine development and treatment of anthrax.
@en
Progress and novel strategies in vaccine development and treatment of anthrax.
@nl
type
label
Progress and novel strategies in vaccine development and treatment of anthrax.
@en
Progress and novel strategies in vaccine development and treatment of anthrax.
@nl
prefLabel
Progress and novel strategies in vaccine development and treatment of anthrax.
@en
Progress and novel strategies in vaccine development and treatment of anthrax.
@nl
P2093
P2860
P1476
Progress and novel strategies in vaccine development and treatment of anthrax.
@en
P2093
Avigdor Shafferman
Shaul Reuveny
Theodor Chitlaru
Zeev Altboum
P2860
P304
P356
10.1111/J.1600-065X.2010.00969.X
P577
2011-01-01T00:00:00Z